NORD Refines Orphan Exclusivity Position
This article was originally published in The Pink Sheet Daily
Executive Summary
Second letter to Waxman suggests that all orphan biologics should get nine years of exclusivity, noting the "challenge to innovation" posed by untreated rare diseases.